No increased risk for thyroid cancer seen with use of GLP1 receptor agonist versus DPP4 inhibitor use, SGLT2 inhibitor use Glucagon-like peptide 1 (GLP1) receptor agonist use does not appear to be associated with an increased risk for thyroid cancer, according to a study published online April 10 in The BMJ. Björn Pasternak, M.D., Ph.D., from...